Is IXHL or MDCX more profitable?

Incannex Healthcare's return on equity of -81.01% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Medicus Pharma N/A -3,137.84% -263.24%

Do analysts recommend MDCX or AGFY?

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 5,546.17%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Medicus Pharma is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MDCX or AGFY more profitable?

Medicus Pharma has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% Agrify -424.11% -185.90% -72.67%

Does the media favor MDCX or AGFY?

In the previous week, Medicus Pharma had 4 more articles in the media than Agrify. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Medicus Pharma's score of -0.10 indicating that Agrify is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Agrify 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MDCX or VERU?

Veru has higher revenue and earnings than Medicus Pharma. Veru is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.46 N/A Veru $16.89M 2.48 -$22.73M -$0.69 N/A

Is MDCX or VERU more profitable?

Veru's return on equity of -47.58% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% Veru N/A -47.58% -35.83%

Does the media prefer MDCX or VERU?

In the previous week, Medicus Pharma had 4 more articles in the media than Veru. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Veru. Veru's average media sentiment score of 0.00 beat Medicus Pharma's score of -0.10 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KPTI or MDCX?

In the previous week, Medicus Pharma had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 beat Medicus Pharma's score of -0.10 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CRVO or MDCX?

CervoMed is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed N/A N/A -$26.97M -$3.22 N/A Medicus Pharma N/A N/A -$35.46M -$2.46 N/A

Is CRVO or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -156.02% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -156.02% -128.34% Medicus Pharma N/A -3,137.84% -263.24%

Does the media refer more to CRVO or MDCX?

In the previous week, Medicus Pharma had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Medicus Pharma and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.99 beat Medicus Pharma's score of -0.10 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Medicus Pharma (MDCX) Competitors

$0.16 0.00 (-2.80%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.16 +0.00 (+1.00%)

As of 08:36 AM Eastern

Compare

MDCX vs. IXHL, AGFY, VERU, KPTI, and CRVO

Should you buy Medicus Pharma stock or one of its competitors? Medicus Pharma's main competitors and comparable companies include Incannex Healthcare (IXHL), Agrify (AGFY), Veru (VERU), Karyopharm Therapeutics (KPTI), and CervoMed (CRVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medicus Pharma compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 423.26%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 5,546.17%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Incannex Healthcare's return on equity of -81.01% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Medicus Pharma	N/A	-3,137.84%	-263.24%

In the previous week, Medicus Pharma had 5 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for Medicus Pharma and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 beat Medicus Pharma's score of -0.10 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Medicus Pharma	Neutral

Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Medicus Pharma has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	457.52	-$46.88M	-$1.55	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

0.4% of Incannex Healthcare shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Incannex Healthcare and Medicus Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to Agrify?

Medicus Pharma (NASDAQ:MDCX) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Medicus Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Agrify has a beta of 9.96, indicating that its stock price is 896% more volatile than the broader market.

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 5,546.17%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Medicus Pharma is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Medicus Pharma has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Agrify	-424.11%	-185.90%	-72.67%

6.0% of Agrify shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Medicus Pharma had 4 more articles in the media than Agrify. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Medicus Pharma's score of -0.10 indicating that Agrify is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agrify	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medicus Pharma has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A

Summary

Medicus Pharma beats Agrify on 9 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Veru?

Medicus Pharma (NASDAQ:MDCX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Veru has higher revenue and earnings than Medicus Pharma. Veru is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A

47.2% of Veru shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Veru has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market.

Veru's return on equity of -47.58% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Veru	N/A	-47.58%	-35.83%

In the previous week, Medicus Pharma had 4 more articles in the media than Veru. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Veru. Veru's average media sentiment score of 0.00 beat Medicus Pharma's score of -0.10 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma currently has a consensus target price of $9.00, indicating a potential upside of 5,546.17%. Veru has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Medicus Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Medicus Pharma is more favorable than Veru.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Veru beats Medicus Pharma on 8 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Medicus Pharma has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.27	-$196.04M	-$13.09	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Karyopharm Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 557.14%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 5,546.17%. Given Medicus Pharma's higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Medicus Pharma had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 5 mentions for Medicus Pharma and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 beat Medicus Pharma's score of -0.10 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Medicus Pharma	N/A	-3,137.84%	-263.24%

Karyopharm Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Medicus Pharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -156.02% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
Medicus Pharma	N/A	-3,137.84%	-263.24%

25.1% of CervoMed shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CervoMed has a beta of -0.64, meaning that its share price is 164% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

CervoMed presently has a consensus price target of $21.00, indicating a potential upside of 736.65%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 5,546.17%. Given Medicus Pharma's higher possible upside, analysts plainly believe Medicus Pharma is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

CervoMed is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	N/A	N/A	-$26.97M	-$3.22	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

In the previous week, Medicus Pharma had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Medicus Pharma and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.99 beat Medicus Pharma's score of -0.10 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CervoMed beats Medicus Pharma on 9 of the 15 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.36M	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.06	792.28	274.10	25.70
Price / Sales	N/A	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	N/A	10.57	10.48	6.32
Net Income	-$35.46M	$2.81B	$3.49B	$359.73M
7 Day Performance	-6.57%	-0.17%	-0.68%	0.17%
1 Month Performance	-38.07%	-1.39%	-3.18%	-3.27%
1 Year Performance	-93.75%	2.83%	15.13%	5.58%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	2.2935 of 5 stars	$0.16 -2.8%	$9.00 +5,546.2%	-94.3%	$10.36M	N/A	N/A	16	Gap Down
IXHL Incannex Healthcare	1.6527 of 5 stars	$3.59 -5.5%	$18.00 +401.4%	-82.9%	$42.97M	$90K	N/A	12
AGFY Agrify	N/A	$20.88 -2.6%	N/A	-40.4%	$41.81M	$12.26M	N/A	140	Gap Down
VERU Veru	2.2261 of 5 stars	$2.39 +3.0%	$24.50 +925.1%	-27.0%	$40.75M	$16.89M	N/A	230
KPTI Karyopharm Therapeutics	2.3721 of 5 stars	$1.79 +5.3%	$11.50 +542.5%	-76.6%	$40.60M	$146.62M	N/A	228

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. IXHL, AGFY, VERU, KPTI, and CRVO

How does Medicus Pharma compare to Incannex Healthcare?

Summary

How does Medicus Pharma compare to Agrify?

Summary

How does Medicus Pharma compare to Veru?

Summary

How does Medicus Pharma compare to Karyopharm Therapeutics?

Summary

How does Medicus Pharma compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. IXHL, AGFY, VERU, KPTI, and CRVO

How does Medicus Pharma compare to Incannex Healthcare?

Do analysts recommend IXHL or MDCX?

Is IXHL or MDCX more profitable?

Does the media prefer IXHL or MDCX?

Which has more volatility & risk, IXHL or MDCX?

Which has higher earnings & valuation, IXHL or MDCX?

Do institutionals & insiders have more ownership in IXHL or MDCX?

Summary

How does Medicus Pharma compare to Agrify?

Which has more volatility and risk, MDCX or AGFY?

Do analysts recommend MDCX or AGFY?

Is MDCX or AGFY more profitable?

Do institutionals and insiders hold more shares of MDCX or AGFY?

Does the media favor MDCX or AGFY?

Which has preferable valuation & earnings, MDCX or AGFY?

Summary

How does Medicus Pharma compare to Veru?

Which has preferable earnings and valuation, MDCX or VERU?

Do insiders and institutionals believe in MDCX or VERU?

Which has more volatility & risk, MDCX or VERU?

Is MDCX or VERU more profitable?

Does the media prefer MDCX or VERU?

Do analysts rate MDCX or VERU?

Summary

How does Medicus Pharma compare to Karyopharm Therapeutics?

Which has higher valuation & earnings, KPTI or MDCX?

Do institutionals and insiders have more ownership in KPTI or MDCX?

Do analysts recommend KPTI or MDCX?

Does the media prefer KPTI or MDCX?

Is KPTI or MDCX more profitable?

Which has more risk & volatility, KPTI or MDCX?

Summary

How does Medicus Pharma compare to CervoMed?

Is CRVO or MDCX more profitable?

Do institutionals and insiders believe in CRVO or MDCX?

Which has more volatility & risk, CRVO or MDCX?

Do analysts recommend CRVO or MDCX?

Which has better earnings & valuation, CRVO or MDCX?

Does the media refer more to CRVO or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools